Shares of Edesa Biotech Inc. (EDSA) are rallying over 160% in pre-market today, after the company announced that it has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients.
from RTT - Before the Bell https://ift.tt/30KZ8WT
via IFTTT
No comments:
Post a Comment